RetinaCME
VIDEOCMEABO MOC

Branching Out to Reduce the Burden of Treatment in Age-related Macular Degeneration and Diabetic Macular Edema: Novel Approaches

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Karl G. Csaky, MD, PhD; Nancy M. Holekamp, MD
Release Date: 5/17/2021Expiration Date: 5/16/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: VideoProvider:
Visual acuity gains demonstrated in pinnacle clinical studies for retinal diseases are difficult to recreate in real-world practice, mainly due to treatment burden and subsequent loss of patient adherence. Novel delivery systems, gene therapy, and agents designed to enhance dosing intervals and/or target novel pathways have the potential to enhance visual acuity outcomes while reducing treatment burden. As a number of these advances move into late-stage clinical trials, familiarity with their utilization is imperative for optimal integration into current management paradigms. In this education activity, experts in the field discuss the need for therapies that have the potential to reduce treatment burden through enhanced duration of action as well as evaluate emerging clinical studies with novel therapies, gene therapy, and emerging delivery systems that have the potential to lengthen time between treatment for patients with retinal diseases.